ANC-501 in the Treatment of Adults With Major Depressive Disorder
Study Details
Study Description
Brief Summary
This is a single-arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and activity of ANC-501 oral capsules as adjunctive treatment in subjects diagnosed with major depressive disorder (MDD)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ANC-501 50 mg/day |
Drug: ANC-501
Five 10 mg capsules per day
|
Outcome Measures
Primary Outcome Measures
- Mean Change from Baseline Montgomery-Asberg Depression Rating Scale (MADRS) Total Score [Baseline (Day 1) to Day 56]
To evaluate the effect of treatment with ANC-501 capsules on depressive symptoms in subjects with major depressive disorder (MDD)
- Treatment-emergent Adverse Events [Baseline (Day 1) up to Day 112]
Incidence and severity of adverse events, including serious adverse events and adverse events leading to study discontinuation and clinically significant changes in vital signs, physical examination endpoints, clinical safety laboratory values and ECGs
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult male or female between 18 and 65 years of age, inclusive.
-
Diagnosis of current episode of major depressive disorder (MDD) at least 8 weeks prior to screening, confirmed by Structured Clinical Interview for DSM-5 - Clinical Trials Version (SCID-5-CT).
-
Have not responded to their current antidepressant therapy or to dose adjustment/treatment changes following a loss of response to their current antidepressant therapy.
-
Receiving a stable dose of the same antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI] monotherapy) for the current episode for at least 8 weeks of continuous treatment with 4 weeks being on a stable dose prior to Day 1 and has an inadequate response (<50% improvement) using the MGH ATRQ.
-
MADRS total score of ≥28 at screening and Day 1 (prior to dosing).
-
Elevation of cortisol as measured by 12-hour urine collection.
Exclusion Criteria:
-
Inadequate response to >2 prior ADTs (not including current antidepressant) of at least 6 weeks duration each for the episode current at screening.
-
Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
-
Administration of drugs to treat a psychiatric or neurologic condition that have been initiated within 8 weeks prior to screening and/or are not being taken at a stable dose (current dose must be stable for 4 weeks preceding screening).
-
Significant findings on ophthalmic examination including, Best Corrected Visual Acuity (BCVA) worse than 20/30 or, in the opinion of the ophthalmologist, any cataract that may become clinically significant and/or need surgical intervention during the course of the trial.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Ancora Bio, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ANC501D0005